Sintilimab plus chemo for resected mucosal melanoma
Treatments studied
Part of Cancer, Immune system & allergy clinical trials.
This trial tests if adding sintilimab (an immunotherapy) to chemotherapy after surgery can lower the chance of mucosal melanoma coming back. It is for people whose melanoma has been fully removed and whose tumor tests positive for PD-L1.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mucosal melanoma that has been completely removed by surgery with clear margins.
- Your tumor must be PD-L1 positive (a lab test shows CPS ≥ 1).
- You start the study drug within 13 weeks after surgery, once the wound has healed.
- You are at least 18 years old and in generally good health (able to care for yourself).
- You have not taken any anti-PD-1 or anti-PD-L1 drugs before.
- You do not have active autoimmune diseases, severe infections, or other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of carilizumab (an immunotherapy drug) and apatinib (a targeted therapy) with radiation therapy for people with advanced mucosal melanoma that has come back or spread. The goal is to see if this triple approach can shrink tumors and help patients live longer.
This trial tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) can clear tiny amounts of cancer cells that remain after surgery in people with high-risk melanoma. It aims to prevent the cancer from coming back.
This trial studies how well two medicines—axitinib and nivolumab—work for people with advanced melanoma that starts in moist “mucosal” areas (like the mouth, nose, throat, or bowel). It may help shrink tumors and control the disease by boosting the immune system and targeting tumor growth.
This trial tests a combination of chemo drugs (paclitaxel polymersomes, carboplatin) and an immunotherapy (adebelimab) before surgery for people with mucosal melanoma that can be removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial studies whether giving pembrolizumab (an immunotherapy) together with a targeted form of radiation can help after surgery for mucosal melanoma. It aims to lower the chance of the cancer coming back and improve outcomes in people whose tumor was removed.
This trial tests whether using the immunotherapy drug sintilimab after surgery, guided by a blood test that looks for tiny bits of cancer DNA (MRD), can help keep non-small cell lung cancer from coming back. It is for people who had immunotherapy before surgery and still had some cancer left after the operation.
Hear when a new Mucosal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.